1254347-06-2

Upstream product

• 108-95-2 phenol 
• 50868-73-0 2-methoxy-6-methylbenzeneamine 
• 1254340-85-6 phenyl 4-bromo-2-methoxy-6-methylbenzoate 
• 1244949-43-6 4-bromo-2-methoxy-6-methyl-benzaldehyde 
• 877149-08-1 4-bromo-2-methoxy-6-methyl-benzoic acid 
• 877149-05-8 4-bromo-2-methoxy-6-methyl-benzonitrile 
• 348169-39-1 4-bromo-2-methoxy-6-methyl-phenylamine 

Downstream Products

• 1335556-22-3 phenyl 4-(benzyloxy)-7-methoxy-6-methyl-2-tert-pentylisoindoline-5-carboxylate 
• 1254347-08-4 phenyl 4-bromo-6-{[(tert-butoxy)carbonyl]oxy}-3-methoxy-2-methylbenzoate 
• 1335557-44-2 C₁₆H₁₃BrO₅ 
• 1335557-45-3 C₂₃H₂₁BrO₅ 
• 1335557-46-4 C₂₄H₂₄O₆ 
• 1335557-47-5 C₂₄H₂₂Cl₂O₄ 
• 1359022-59-5 phenyl 2-(benzyloxy)-4-bromo-6-methylbenzoate 
• 1359021-53-6 C₄₈H₅₉N₃O₈Si 
• 1359021-63-8 C₄₂H₄₅N₃O₈ 
• 1254351-84-2 C₂₂H₁₉BrO₄ 
• 1359021-86-5 C₃₁H₃₅NO₈ 
• 1359021-87-6 C₂₆H₂₅NO₅ 
• 1359021-88-7 C₁₉H₂₁NO₅ 
• 1359021-89-8 C₂₅H₃₁NO₇ 

Relevant academic research and scientific papers

Tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Synthesis and biological evaluation of 8-aminomethyltetracycline derivatives as novel antibacterial agents

The C-8 position of the tetracyclines has been largely underexplored because of limitations in traditional semisynthetic techniques. Employing a total synthetic approach allowed for modifications at the C-7 and C-8 positions, enabling the generation of structure-activity relationships for overcoming the two most common tetracycline bacterial-resistance mechanisms: ribosomal protection (tet(M)) and efflux (tet(A)). Ultimately, several compounds were identified with balanced activity against both Gram-positive and Gram-negative bacteria, including pathogens bearing both types of tetracycline-resistance mechanisms. Compounds were screened in a murine systemic infection model to rapidly identify compounds with oral bioavailability, leading to the discovery of several compounds that exhibited efficacy when administered orally in murine pyelonephritis and pneumonia models.

TETRACYCLINE ANALOGS

The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

POLYCYCLIC TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.